AKI not only poses an immediate threat to the patients' health but also significantly increases the risk of developing a chronic kidney disease (CKD), potentially leading to long-term renal damage and other serious health complications, including renal cancer.
Understanding the dynamics of acute kidney injury is essential for developing effective kidney disease treatments and improving patient outcomes. At Central BioHub, we are committed to advancing research in this pivotal area by providing researchers with high-quality, accessible bio-samples essential for studying AKI and its progression.
Sample Specifications for AKI Research:
ICD-10 Code: We offer AKI research samples with ICD-10 classification N17 that gives researchers access to clinically relevant and specific cases of acute kidney injury.
Matrix: We provide a diverse range of matrices, including plasma, serum, and urine, to support multifaceted studies into AKI and related kidney diseases.
Acute Kidney Failure Focus: Each sample is carefully selected to represent multiple cases of acute kidney failure, providing a rich foundation for studying the condition's onset, progression, and outcomes.
Comprehensive Test Methods: With 10 different test methods available, ranging from cutting-edge to standard assays, researchers can apply a broad spectrum of analytical techniques to investigate our samples. This versatility enhances the depth and breadth of AKI research, facilitating innovative approaches to understanding kidney health.
Through our support of AKI research, Central BioHub aims to play a crucial role in the development of new kidney disease treatments and our understanding of kidney health. By offering high-quality, research-ready biospecimens, we empower scientists and researchers to uncover new insights into AKI, its consequences, and its treatment.
Explore advanced search options for procuring Kidney disease samples by clicking clinical diagnosis, ICD-10-CM codes, and laboratory parameters.